Kerecis to Present at NASDAQ OMX

REYKJAVIK, ICELAND and ISAFJORDUR, ICELAND--(Marketwired - May 23, 2014) - Kerecis Limited, the emerging leader in tissue-regeneration materials, will participate in the NASDAQ OMX Iceland Prospect Conference on Tuesday, May 27, at 2:15 pm. The conference will take place in the Harpa Conference Centre in Reykjavik, Iceland.

The NASDAQ OMX conference will connect Kerecis and 10 other early-stage companies with corporate investors. The conference is a part of NASDAQ OMX's effort to support financial growth and help entrepreneurs get the funding they need.

Kerecis is the developer of the Kerecis Omega3 fish-skin regenerative surgical materials for multiple indications, including treatment of wounds and breast reconstruction. The first Kerecis product, Kerecis Omega3 Wound, is already on the market and is indicated for the management of chronic wounds including diabetic, vascular and other hard-to-heal wounds. Materials indicated for hernia and dura repair are also under development.

When inserted into or onto damaged human tissue, the Kerecis Omega3 products recruit the body's own cells, are incorporated into the wound, and ultimately are converted into functional, living tissue.

Statements:

G. Fertram Sigurjonsson, CEO, President and Chairman Kerecis Limited
"As our business advances we are happy to share our progress with the customers of NASDAQ OMX. We are making good progress in developing our technology beyond its currently approved use as a treatment for chronic wounds. Our goal is to develop a procedurally integrated platform that could potentially transform how tissue damage is treated across multiple indications, such as hernia repair, breast reconstruction and dura repair."

About Kerecis

Kerecis develops and produces tissue-regeneration biologic matrixes consisting of patented Omega3-containing fish skin. Biologic matrixes are materials made from human or animal tissue where the original material is intact, but all cells and antigenic materials have been removed. The Kerecis fish-skin material accelerates wound healing and enables tissue reconstruction.

This FDA-approved material offers advantages over existing human- and porcine-derived products, including improved manufacturing economics and a lower risk of disease transfer. Since it is derived from fish, the material is both kosher and halal compatible, eliminating cultural and religious constraints to usage, with equivalent or better clinical performance than alternative approaches.

The Kerecis material has received a U.S. patent, and has patents pending in multiple countries around the world. The materials are available in Iceland, Denmark, the UK, Turkey and several Middle East and Asian markets. Distributor inquiries are welcome. For more information, visit www.kerecis.com.